|
source DB |
source ID
|
text
|
size
|
updated at |
|
# proj.
|
|
# Ann.
|
updated_at |
| PubMed |
32284362 |
COVID-19 and neuromuscular disorders.
The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and severely affect patients with neuromuscular disorders. In a short period of time, |
1.04 KB |
2020-05-07 |
|
22 |
|
0 |
2021-01-18
|
| PubMed |
32282982 |
Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.
COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ t |
1.48 KB |
2020-05-07 |
|
2 |
|
0 |
2021-01-18
|
| PubMed |
32282502 |
Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).
A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the glo |
1.04 KB |
2020-05-07 |
|
2 |
|
4 |
2021-01-18
|
| PubMed |
32323646 |
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings.
The novel severe a |
1.9 KB |
2020-05-07 |
|
24 |
|
1 |
2021-01-18
|
| PubMed |
32321905 |
Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
In late March and early April 2020, the antimalarial |
1.83 KB |
2020-05-07 |
|
22 |
|
9 |
2021-01-18
|
| PubMed |
32321878 |
Is GSK3β a molecular target of chloroquine treatment against COVID-19?
The recent clinical trial reports pertaining to the efficacy of chloroquine and hydroxychloroquine against COVID-19 albeit yet to |
1021 Bytes |
2020-05-07 |
|
23 |
|
0 |
2021-01-18
|
| PubMed |
32408070 |
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
Currently, drug repurposing is an alternative to novel drug developmen |
1.21 KB |
2020-05-18 |
|
5 |
|
1 |
2021-01-18
|
| PubMed |
32387694 |
Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe ac |
1.55 KB |
2020-05-18 |
|
5 |
|
0 |
2021-01-18
|
| PubMed |
32402766 |
Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
Covid-19 is a new coronavirus disease first described in December 2019. Thi |
2.55 KB |
2020-05-18 |
|
5 |
|
4 |
2021-01-18
|
| PubMed |
32373993 |
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
OBJECTIVE: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called COVID-19, has caused a pande |
2.61 KB |
2020-05-18 |
|
25 |
|
0 |
2021-01-18
|
